Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer

The Journal of Urology
Kees HendricksenJ Alfred Witjes

Abstract

We studied the safety and efficacy of multiple adjuvant apaziquone instillations in patients with high risk nonmuscle invasive bladder cancer. Patients with high risk nonmuscle invasive urothelial carcinoma of the bladder underwent transurethral resection of all bladder tumor(s), and received 6 weekly adjuvant intravesical apaziquone instillations of 4 mg in 40 ml. Patients with carcinoma in situ received 3 further maintenance instillations at months 3, 6 and 12. Followup consisted of cystoscopy, urine cytology and observation of adverse events every 3 months for 18 months. A total of 53 patients were enrolled in the study. Although all patients were high risk according to the definitions used when the study was initiated, according to most recent guideline criteria, 80% and 20% of these patients would now be considered intermediate and high risk for recurrence, and 50% and 44% would be considered intermediate and high risk for progression, respectively. Intent to treat analysis of 49 patients with papillary tumors showed recurrent tumors in 34.7% and 44.9% at 12 and 18 months, respectively. One patient had progression to T2 or greater urothelial carcinoma after 9 months. There were 4 patients with carcinoma in situ who had com...Continue Reading

References

Oct 1, 1992·British Journal of Urology·R J Van ThielN P Tjon Pian Gi
Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·P WorkmanK L Kooistra
Mar 1, 1992·British Journal of Cancer·R M PhillipsJ A Double
Apr 1, 1996·The Journal of Urology·A BohleD Jocham
Aug 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H L McLeodB Lund
Jun 21, 2002·European Urology·Willem OosterlinckUNKNOWN European Association of Urology (EAU) Working Group on Oncological Urology
Oct 16, 2003·The Medical Journal of Australia·Stephane R HeritierAnthony C Keech
Jan 10, 2006·Urology·Ziya KirkaliJeff Weider
Nov 13, 2007·The Journal of Urology·M Craig HallPaul F Schellhammer
Jun 14, 2008·Expert Opinion on Investigational Drugs·J Alfred Witjes, Prasad S Kolli

❮ Previous
Next ❯

Citations

Jul 13, 2013·Chinese Journal of Cancer·Christopher P GuiseKe Ding
Feb 5, 2014·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Brant A InmanZeljko Vujaskovic
Aug 21, 2013·Expert Opinion on Biological Therapy·Anna V van Lingen, J Alfred Witjes
Apr 19, 2016·European Journal of Medicinal Chemistry·K Jones M SwapnajaKiran Kumar Sriram
Jun 3, 2015·Nature Reviews. Urology·Carolyn Ritterson LewDan Theodorescu
Apr 18, 2015·The Urologic Clinics of North America·Brock E Boehm, Robert S Svatek
Jun 24, 2017·Expert Opinion on Drug Metabolism & Toxicology·R M PhillipsG J Peters
Dec 2, 2015·Therapeutic Advances in Urology·Dominic H Tang, Sam S Chang
May 8, 2018·Expert Opinion on Emerging Drugs·Jasper Crijnen, Theo M De Reijke
Oct 17, 2017·Expert Opinion on Pharmacotherapy·Francisco Caramés Masana, Theo M de Reijke
Mar 2, 2016·Annals of Biomedical Engineering·Jicheng YuZhen Gu
Apr 2, 2014·Current Opinion in Oncology·Monalisa GhoshAndrea B Apolo
Mar 19, 2014·Current Opinion in Oncology·Jeffrey C BassettPeter E Clark
Oct 1, 2019·Current Opinion in Urology·Francesca PisanoJ Palou
Jan 11, 2021·Journal of Experimental & Clinical Cancer Research : CR·Bin WangXin Jiang
May 2, 2018·Journal of Medicinal Chemistry·Kuojun ZhangSheng Jiang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.